# A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care

> **NCT05195749** · PHASE2 · TERMINATED · sponsor: **101 Therapeutics** · enrollment: 3 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** 101-PGC-005 ('005) + SOC
- **DRUG:** Placebo + SOC

## Key facts

- **NCT ID:** NCT05195749
- **Lead sponsor:** 101 Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-13
- **Primary completion:** 2023-02-14
- **Final completion:** 2023-02-14
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Low Enrollment
- **Last updated:** 2023-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05195749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05195749, "A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05195749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*